Go here to see the original: Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development...
Excerpt from: Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with...
Follow this link: Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Read this article: ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
View post: Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
View post: Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
View post: Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
Read more: Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
See the article here: Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
Recent Comments